Spyre Therapeutics的锁定期将于2025年12月13日结束，解除了对股票销售的限制，此前已暂停60天。 Spyre Therapeutics' lock-up period ends Dec. 13, 2025, lifting restrictions on share sales after a 60-day hold.

根据2025年10月13日起实行的61天限制,2025年12月13日到期的2025年12月13日之前,某些Spyre疗法股份,包括RSU、A系列和B类首选股票以及共同股份,须遵守一项封闭协议。 Certain shares of Spyre Therapeutics, including RSUs, Series A and B Preferred Stock, and common shares, are subject to a lock-up agreement ending December 13, 2025, following a 61-day restriction starting October 13, 2025. 执行官员和董事不得出售或转让这些股份,但特定例外除外。 Executive officers and directors are barred from selling or transferring these shares, except under specific exceptions. 限制措施在计划书日期后第60天交易结束后解除,目的是防止市场中断,并在公司公开出价后稳定股票价格。 The restriction lifts after the close of trading on the 60th day following the prospectus date, aiming to prevent market disruption and stabilize the stock price after the company’s public offering.